Skip to content
Hepatx logo

Hepatx

Hepatx is a YC Summer 2018 (S18) company. Based in Palo Alto, CA, USA. Team of 4.

  • Biotech

About Hepatx

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Hepatx develops off-the-shelf, stem cell-based therapies for patients with end-stage liver disease, positioning the treatment as a direct alternative to liver transplant. The therapy targets the roughly 200,000 Americans each year who reach end-stage liver failure and face a severe shortage of donor organs. The work it replaces is organ transplant surgery, along with the prolonged waiting and high mortality that comes with relying on donor availability.

Business model

Cell therapy treatments sold as off-the-shelf infusion products to replace organ transplant procedures.

Go-to-market

Hepatx targets late-stage liver disease patients who cannot access a donor organ in time, with a scalable manufacturing process designed to make the therapy practical for broad clinical deployment.

From the Y Combinator listing

How Hepatx describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Replacing organ transplant with an infusion

Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Palo Alto, CA, USA
Team size
4
Status
Active
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works